In a regulatory filing, the company said that Biocon Biologics has has signed a settlement and license agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson, collectively known as Janssen. This pact enables Biocon Biologics to commercialize its Bmab 1200, a proposed biosimilar to Stelara, in Europe, the United Kingdom (UK), Canada, and Japan. Under the terms of this settlement agreement, Biocon Biologics has resolved patent disputes with Janssen to secure market entry dates in the above mentioned regions. Regulatory filings for Bmab 1200 are currently under review. Stelara (Ustekinumab) is a monoclonal antibody medication that prevents abnormal regulation of interleukin IL-12/23 associated immune diseases and has been approved for the treatment of psoriasis, Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. The reference brand, Stelara, had worldwide sales of $10.85 billion in 2023. Shreehas Tambe, CEO & managing director, Biocon Biologics, said, 'This settlement agreement is testament to our proven track record of science and innovation and is another key milestone in our journey to bring our biosimilar Bmab 1200 (bUstekinumab) to global markets. Bmab 1200 will significantly strengthen our immunology franchise, enabling us to offer an affordable and effective treatment option for patients impacted by autoimmune diseases.' Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025, once approved by the U.S. FDA. The U.S. FDA has accepted the company's Biologics License Application (BLA) for Bmab 1200 (bUstekinumab) for review under the 351(k) pathway. Biocon is an innovation led global biopharmaceuticals company, engaged in the production of therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. The company's conosldidated net profit surged to Rs 659.7 crore in Q1 FY25 as compared with Rs 101.4 crore in Q1 FY24. Revenue from operations increased marginally year on year to Rs 3,432.9 crore in during the quarter. Shares of Biocon shed 0.81% to Rs 354 on the BSE. Powered by Capital Market - Live

Biocon Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 358.2, up 0.9% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.22% on the day, quoting at 24824.75. The Sensex is at 81098.08, up 0.24%. Biocon Ltd has risen around 6.28% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has risen around 8.74% in last one month and is currently quoting at 22577.9, down 0.04% on the day. The volume in the stock stood at 16.17 lakh shares today, compared to the daily average of 43.38 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 359.2, up 1.13% on the day. Biocon Ltd is up 37.58% in last one year as compared to a 27.67% spurt in NIFTY and a 47.68% spurt in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending June 24.Powered by Capital Market - Live

Biocon Ltd gained for a third straight session today. The stock is quoting at Rs 348.6, up 1.1% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.57% on the day, quoting at 24712.8. The Sensex is at 80888.47, up 0.58%. Biocon Ltd has risen around 3.95% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has risen around 7.97% in last one month and is currently quoting at 22237.85, up 0.22% on the day. The volume in the stock stood at 34.09 lakh shares today, compared to the daily average of 43.07 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 348.95, up 1.16% on the day. Biocon Ltd is up 34.36% in last one year as compared to a 27.43% spurt in NIFTY and a 45.34% spurt in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending June 24.Powered by Capital Market - Live

Revenue from operations increased marginally YoY to Rs 3,432.9 crore in during the quarter. Total income jumped 29.9% to Rs 4,567.4 crore in Q1 FY25 as compared with Rs 3,516.1 crore in Q1 FY24. It includes proceeds of Rs 1,057 crore on account of the strategic collaboration between Biocon Biologics & Eris Lifesciences. Profit before exceptional items and tax stood at Rs 1113.5 crore in Q1 FY25, steeply higher than Rs 183.7 crore in Q1 FY24. Exceptional items stood at Rs 320 crore in Q1 FY25. During the quarter, EBITDA soared to Rs 1,755 crore as compared with Rs 808 crore posted in same quarter last fiscal. EBITDA margins expanded to 38% in Q1 FY25 as against 23% in Q1 FY24. Net R&D expenses fell 28% to Rs 228 crore during the quarter from Rs 315 crore recorded in corresponding quarter last year, representing 9% of revenue ex-Syngene. On segmental front, revenue from biosimilar stood at Rs 2,083 crore in Q1 FY25, up 3% from Rs 2,015 crore in Q1 FY24. On like-for-like basis, revenue jumped 11%. Revenue does not include proceeds of Rs 1,057 core on account of the strategic collaboration and business transfer to Eris Lifesciences which is booked as other income. Income from generics business fell 6% to Rs 659 crore in the first quarter of FY25 as compared with Rs 700 crore in Q1 FY24 and Revenue from research services (Syngene) declined 2% YoY to Rs 790 crore in Q1 FY25. Kiran Mazumdar-Shaw, executive chairperson, Biocon and Biocon Biologics, said, 'The outlook for this fiscal remains positive as we anticipate stronger growth in H2FY25, with new product launches in the Biosimilars and Generics businesses, including Liraglutide for diabetes and obesity in the UK and other markets. Additionally, we expect improved business prospects for Syngene, supported by a resurgent biotech funding environment in the U.S. Siddharth Mittal, CEO & managing director, Biocon, said, 'The Generics business continued to encounter pricing pressure and demand contraction, which impacted our first quarter's performance of both APIs and Generic Formulations. The business made progress on its Most of the World (MoW) expansion strategy with the signing of a partnership agreement with Handok in South Korea for the commercialization of Liraglutide. We also obtained our first injectable approval in the U.S. for Micafungin and secured some key customer contracts in the region. Looking ahead, our focus will be directed towards commercializing products for which we have received approvals, including Liraglutide, in the second half of this fiscal, as indicated previously. We will also continue to accelerate our cost improvement initiatives and expedite on-going capex projects.' Shreehas Tambe, CEO & managing director, Biocon Biologics, said, 'We began the fiscal year on a strong note with the business delivering year-on-year growth of 11% on a like-for-like basis. This growth was underpinned by an increase in market shares, tender wins in Europe and Emerging Markets and 15 new product launches.' Jonathan Hunt, CEO & managing director, Syngene International, said, ''First quarter performance was broadly flat, in line with our expectations, reflecting the dip in funding for U.S. biotechs that has impacted our sector over the last two years. However, the value of U.S. biotech funding has seen a marked improvement in the first half of 2024. It will take a while for this funding to flow through into outsourcing activities and Syngene is in a strong position to capture a significant share of the upturn in biotech spending in the months ahead.' Biocon is an innovation led global biopharmaceuticals company, engaged in the production of therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. The counter shed 0.57% to Rs 337.25 on the BSE.Powered by Capital Market - Live

Net profit of Biocon rose 550.59% to Rs 659.70 crore in the quarter ended June 2024 as against Rs 101.40 crore during the previous quarter ended June 2023. Sales rose 0.30% to Rs 3432.90 crore in the quarter ended June 2024 as against Rs 3422.60 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales3432.903422.60 0 OPM %18.0719.90 - PBDT1518.90541.70 180 PBT1113.50183.70 506 NP659.70101.40 551 Powered by Capital Market - Live